IDEXX Laboratories (IDXX) vs IQVIA (IQV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
IQVIA (IQV) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 29.1% versus a loss of 18.5%. Over five years, IQV leads with a +4.0% price change compared with -19.2% for IDXX. IQVIA is the larger company by market cap ($43.09 billion vs $40.90 billion), about 1.1 times the size, while IDEXX Laboratories is growing revenue faster (+10.4% vs +5.9%).
On valuation, IQVIA trades at a lower forward P/E (18.1x vs 31.0x for IDEXX Laboratories). IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus 8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | IQV |
|---|---|---|
| Share price | $519.16 | $261.79 |
| Market cap | $40.90B | $43.09B |
| 1-day change | +1.17% | +1.12% |
| YTD return | -24.15% | +14.85% |
| 1-year return | -18.54% | +29.05% |
| 5-year return | -19.21% | +4.03% |
| P/E ratio (TTM) | 36.48 | 32.52 |
| Forward P/E | 31.02 | 18.14 |
| EPS (TTM) | $14.23 | $8.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $16.31B |
| Revenue growth (YoY) | +10.42% | +5.87% |
| Net income (latest FY) | $1.06B | $1.36B |
| Gross margin | 61.80% | 33.29% |
| Operating margin | 31.60% | 13.38% |
| Net margin | 24.62% | 8.34% |
| 52-week high | $769.98 | $277.40 |
| 52-week low | $500.61 | $154.50 |
| Distance from 52-week high | -32.58% | -5.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +35.09% | +11.10% |
| Average volume | 553.95K | 1.45M |
| Shares outstanding | 78.78M | 164.60M |
| Employees | 11,000 | 94,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IQV has outperformed IDXX by 47.6 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus 8.3 cents for IQVIA.
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About IQVIA
IQV stock →IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 94,000 employees
IDXX vs IQV FAQ
Which is bigger, IDEXX Laboratories or IQVIA?
IQVIA (IQV) is larger, with a market capitalization of $43.09B compared with $40.90B for IDEXX Laboratories (IDXX).
Which stock has performed better over the past year, IDXX or IQV?
IQV returned +29.05% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IDXX or IQV?
IQV has the lower trailing P/E at 32.5, versus 36.5 for IDXX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are IDEXX Laboratories and IQVIA in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for IDEXX Laboratories and Biotechnology: Commercial Physical & Biological Resarch for IQVIA.